NTRA vs PSNL
NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications. PSNL: Personalis provides ultra-sensitive cancer genomic testing and MRD monitoring to enable personalized cancer therapy and translational research at scale.
Side-by-side fundamentals
| Metric | NTRA | PSNL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $390.79 | $16.06 | |
| Market cap | $56.3B | $1.7B | |
| Net margin FY2025, SEC XBRL | -9.0% | -116.7% | NTRA higher |
| Operating margin FY2025, SEC XBRL | -13.4% | -126.4% | NTRA higher |
| ROE FY2025, SEC XBRL | -12.2% | -31.1% | NTRA higher |
| ROA FY2025, SEC XBRL | -8.7% | -24.3% | NTRA higher |
| Debt / equity as of 2026-09-03 | 0.04 | 0.00 | PSNL lower |
| Revenue growth (YoY) as of 2026-09-03 | +37.8% | -13.3% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +2.3% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.29 | 2.05 | |
| 1-year return as of 2026-10-08 close | +127.1% | +85.0% | NTRA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.